Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 57 entries
Sorted by: Best Match Show Resources per page
Regulatory elements in noncoding DNA in the chromosome 9p21 locus.

Circulation. Cardiovascular genetics

Musunuru K.
PMID: 21673313
Circ Cardiovasc Genet. 2011 Jun;4(3):330-1. doi: 10.1161/CIRCGENETICS.111.960500.

No abstract available.

Cite
Musunuru K. Regulatory elements in noncoding DNA in the chromosome 9p21 locus. Circ Cardiovasc Genet. 2011;4(3):330-1doi: 10.1161/CIRCGENETICS.111.960500.
Musunuru, K. (2011). Regulatory elements in noncoding DNA in the chromosome 9p21 locus. Circulation. Cardiovascular genetics, 4(3), 330-1. https://doi.org/10.1161/CIRCGENETICS.111.960500
Musunuru, Kiran. "Regulatory elements in noncoding DNA in the chromosome 9p21 locus." Circulation. Cardiovascular genetics vol. 4,3 (2011): 330-1. doi: https://doi.org/10.1161/CIRCGENETICS.111.960500
Musunuru K. Regulatory elements in noncoding DNA in the chromosome 9p21 locus. Circ Cardiovasc Genet. 2011 Jun;4(3):330-1. doi: 10.1161/CIRCGENETICS.111.960500. PMID: 21673313.
Copy Download .nbib Format: NLM
Mapping Novel Pathways in Cardiovascular Disease Using eQTL Data: The Past, Present, and Future of Gene Expression Analysis.

Frontiers in genetics

Gupta RM, Musunuru K.
PMID: 23755065
Front Genet. 2013 May 31;3:232. doi: 10.3389/fgene.2012.00232. eCollection 2012.

Genome-wide association studies (GWAS) have identified genetic variants associated with numerous cardiovascular and metabolic diseases. Newly identified polymorphisms associated with myocardial infarction, dyslipidemia, hypertension, diabetes, and insulin resistance suggest novel mechanistic pathways that underlie these and other complex diseases....

Cite
Gupta RM, Musunuru K. Mapping Novel Pathways in Cardiovascular Disease Using eQTL Data: The Past, Present, and Future of Gene Expression Analysis. Front Genet. 2013;3:232doi: 10.3389/fgene.2012.00232.
Gupta, R. M., & Musunuru, K. (2012). Mapping Novel Pathways in Cardiovascular Disease Using eQTL Data: The Past, Present, and Future of Gene Expression Analysis. Frontiers in genetics, 3232. https://doi.org/10.3389/fgene.2012.00232
Gupta, Rajat M, and Musunuru, Kiran. "Mapping Novel Pathways in Cardiovascular Disease Using eQTL Data: The Past, Present, and Future of Gene Expression Analysis." Frontiers in genetics vol. 3 (2012): 232. doi: https://doi.org/10.3389/fgene.2012.00232
Gupta RM, Musunuru K. Mapping Novel Pathways in Cardiovascular Disease Using eQTL Data: The Past, Present, and Future of Gene Expression Analysis. Front Genet. 2013 May 31;3:232. doi: 10.3389/fgene.2012.00232. eCollection 2012. PMID: 23755065; PMCID: PMC3668154.
Copy Download .nbib Format: NLM
Haemothorax and thoracic spine fractures in the elderly.

Case reports in radiology

Masteller MA, Chauhan A, Musunuru H, Walsh MM, Boyer B, Prahlow JA.
PMID: 22973528
Case Rep Radiol. 2012;2012:162064. doi: 10.1155/2012/162064. Epub 2012 Sep 02.

Both osteoporotic fractures and pleural effusions are frequently observed in medicine. However, rarely does one associate a hemorrhagic pleural effusion with a thoracic spinal fracture when the patient has not sustained massive trauma. In this paper, we discuss two...

Cite
Masteller MA, Chauhan A, Musunuru H, et al. Haemothorax and thoracic spine fractures in the elderly. Case Rep Radiol. 2012;2012:162064doi: 10.1155/2012/162064.
Masteller, M. A., Chauhan, A., Musunuru, H., Walsh, M. M., Boyer, B., & Prahlow, J. A. (2012). Haemothorax and thoracic spine fractures in the elderly. Case reports in radiology, 2012162064. https://doi.org/10.1155/2012/162064
Masteller, Michael A, et al. "Haemothorax and thoracic spine fractures in the elderly." Case reports in radiology vol. 2012 (2012): 162064. doi: https://doi.org/10.1155/2012/162064
Masteller MA, Chauhan A, Musunuru H, Walsh MM, Boyer B, Prahlow JA. Haemothorax and thoracic spine fractures in the elderly. Case Rep Radiol. 2012;2012:162064. doi: 10.1155/2012/162064. Epub 2012 Sep 02. PMID: 22973528; PMCID: PMC3437616.
Copy Download .nbib Format: NLM
Integrative Analysis of PRKAG2 Cardiomyopathy iPS and Microtissue Models Identifies AMPK as a Regulator of Metabolism, Survival, and Fibrosis.

Cell reports

Hinson JT, Chopra A, Lowe A, Sheng CC, Gupta RM, Kuppusamy R, O'Sullivan J, Rowe G, Wakimoto H, Gorham J, Burke MA, Zhang K, Musunuru K, Gerszten RE, Wu SM, Chen CS, Seidman JG, Seidman CE.
PMID: 28614725
Cell Rep. 2017 Jun 13;19(11):2410. doi: 10.1016/j.celrep.2017.05.038.

No abstract available.

Cite
Hinson JT, Chopra A, Lowe A, et al. Integrative Analysis of PRKAG2 Cardiomyopathy iPS and Microtissue Models Identifies AMPK as a Regulator of Metabolism, Survival, and Fibrosis. Cell Rep. 2017;19(11):2410doi: 10.1016/j.celrep.2017.05.038.
Hinson, J. T., Chopra, A., Lowe, A., Sheng, C. C., Gupta, R. M., Kuppusamy, R., O'Sullivan, J., Rowe, G., Wakimoto, H., Gorham, J., Burke, M. A., Zhang, K., Musunuru, K., Gerszten, R. E., Wu, S. M., Chen, C. S., Seidman, J. G., & Seidman, C. E. (2017). Integrative Analysis of PRKAG2 Cardiomyopathy iPS and Microtissue Models Identifies AMPK as a Regulator of Metabolism, Survival, and Fibrosis. Cell reports, 19(11), 2410. https://doi.org/10.1016/j.celrep.2017.05.038
Hinson, J Travis, et al. "Integrative Analysis of PRKAG2 Cardiomyopathy iPS and Microtissue Models Identifies AMPK as a Regulator of Metabolism, Survival, and Fibrosis." Cell reports vol. 19,11 (2017): 2410. doi: https://doi.org/10.1016/j.celrep.2017.05.038
Hinson JT, Chopra A, Lowe A, Sheng CC, Gupta RM, Kuppusamy R, O'Sullivan J, Rowe G, Wakimoto H, Gorham J, Burke MA, Zhang K, Musunuru K, Gerszten RE, Wu SM, Chen CS, Seidman JG, Seidman CE. Integrative Analysis of PRKAG2 Cardiomyopathy iPS and Microtissue Models Identifies AMPK as a Regulator of Metabolism, Survival, and Fibrosis. Cell Rep. 2017 Jun 13;19(11):2410. doi: 10.1016/j.celrep.2017.05.038. PMID: 28614725.
Copy Download .nbib Format: NLM
A Feasibility Study on the Role of Ultrasound Imaging of Bladder Volume as a Method to Improve Concordance of Bladder Filling Status on Treatment with Simulation.

Journal of medical imaging and radiation sciences

Nathoo D, Loblaw A, Davidson M, Musunuru HB, Khojaste A, Ravi A.
PMID: 32074054
J Med Imaging Radiat Sci. 2018 Sep;49(3):277-285. doi: 10.1016/j.jmir.2018.04.031. Epub 2018 Jun 22.

PURPOSE: Accurate positioning of the prostate is of paramount importance to ensure optimal target coverage and normal tissue sparing in stereotactic ablative body radiation when large doses per fraction are delivered with tight margins around the prostate. Bladder and...

Cite
Nathoo D, Loblaw A, Davidson M, et al. A Feasibility Study on the Role of Ultrasound Imaging of Bladder Volume as a Method to Improve Concordance of Bladder Filling Status on Treatment with Simulation. J Med Imaging Radiat Sci. 2018;49(3):277-285doi: 10.1016/j.jmir.2018.04.031.
Nathoo, D., Loblaw, A., Davidson, M., Musunuru, H. B., Khojaste, A., & Ravi, A. (2018). A Feasibility Study on the Role of Ultrasound Imaging of Bladder Volume as a Method to Improve Concordance of Bladder Filling Status on Treatment with Simulation. Journal of medical imaging and radiation sciences, 49(3), 277-285. https://doi.org/10.1016/j.jmir.2018.04.031
Nathoo, Dilshad, et al. "A Feasibility Study on the Role of Ultrasound Imaging of Bladder Volume as a Method to Improve Concordance of Bladder Filling Status on Treatment with Simulation." Journal of medical imaging and radiation sciences vol. 49,3 (2018): 277-285. doi: https://doi.org/10.1016/j.jmir.2018.04.031
Nathoo D, Loblaw A, Davidson M, Musunuru HB, Khojaste A, Ravi A. A Feasibility Study on the Role of Ultrasound Imaging of Bladder Volume as a Method to Improve Concordance of Bladder Filling Status on Treatment with Simulation. J Med Imaging Radiat Sci. 2018 Sep;49(3):277-285. doi: 10.1016/j.jmir.2018.04.031. Epub 2018 Jun 22. PMID: 32074054.
Copy Download .nbib Format: NLM
Pharmacokinetics and ADME Characterization of Intravenous and Oral [.

Drug metabolism and disposition: the biological fate of chemicals

Zamek-Gliszczynski MJ, Kenworthy D, Bershas DA, Sanghvi M, Pereira AI, Mudunuru J, Crossman L, Pirhalla JL, Thorpe KM, Dennison JMTJ, McLaughlin MM, Allinder M, Swift B, O'Connor-Semmes RL, Young GC.
PMID: 34625435
Drug Metab Dispos. 2021 Dec;49(12):1109-1117. doi: 10.1124/dmd.121.000595. Epub 2021 Oct 08.

Linerixibat, an oral small-molecule ileal bile acid transporter inhibitor under development for cholestatic pruritus in primary biliary cholangitis, was designed for minimal absorption from the intestine (site of pharmacological action). This study characterized the pharmacokinetics, absorption, metabolism, and excretion...

Cite
Zamek-Gliszczynski MJ, Kenworthy D, Bershas DA, et al. Pharmacokinetics and ADME Characterization of Intravenous and Oral [. Drug Metab Dispos. 2021;49(12):1109-1117doi: 10.1124/dmd.121.000595.
Zamek-Gliszczynski, M. J., Kenworthy, D., Bershas, D. A., Sanghvi, M., Pereira, A. I., Mudunuru, J., Crossman, L., Pirhalla, J. L., Thorpe, K. M., Dennison, J. M. T. J., McLaughlin, M. M., Allinder, M., Swift, B., O'Connor-Semmes, R. L., & Young, G. C. (2021). Pharmacokinetics and ADME Characterization of Intravenous and Oral [. Drug metabolism and disposition: the biological fate of chemicals, 49(12), 1109-1117. https://doi.org/10.1124/dmd.121.000595
Zamek-Gliszczynski, Maciej J, et al. "Pharmacokinetics and ADME Characterization of Intravenous and Oral [." Drug metabolism and disposition: the biological fate of chemicals vol. 49,12 (2021): 1109-1117. doi: https://doi.org/10.1124/dmd.121.000595
Zamek-Gliszczynski MJ, Kenworthy D, Bershas DA, Sanghvi M, Pereira AI, Mudunuru J, Crossman L, Pirhalla JL, Thorpe KM, Dennison JMTJ, McLaughlin MM, Allinder M, Swift B, O'Connor-Semmes RL, Young GC. Pharmacokinetics and ADME Characterization of Intravenous and Oral [. Drug Metab Dispos. 2021 Dec;49(12):1109-1117. doi: 10.1124/dmd.121.000595. Epub 2021 Oct 08. PMID: 34625435.
Copy Download .nbib Format: NLM
Therapeutic application of genome editing in dyslipidemia.

Current opinion in lipidology

Whittaker MN, Musunuru K.
PMID: 34907967
Curr Opin Lipidol. 2021 Dec 13; doi: 10.1097/MOL.0000000000000805. Epub 2021 Dec 13.

PURPOSE OF REVIEW: To summarize recent advances with respect to the use of genome editing to modify blood lipid levels in vivo.RECENT FINDINGS: Genome-editing technologies have been successfully used to target the PCSK9 gene in the livers of nonhuman...

Cite
Whittaker MN, Musunuru K. Therapeutic application of genome editing in dyslipidemia. Curr Opin Lipidol. 2021;doi: 10.1097/MOL.0000000000000805.
Whittaker, M. N., & Musunuru, K. (2021). Therapeutic application of genome editing in dyslipidemia. Current opinion in lipidology, . https://doi.org/10.1097/MOL.0000000000000805
Whittaker, Madelynn N, and Musunuru, Kiran. "Therapeutic application of genome editing in dyslipidemia." Current opinion in lipidology vol. (2021). doi: https://doi.org/10.1097/MOL.0000000000000805
Whittaker MN, Musunuru K. Therapeutic application of genome editing in dyslipidemia. Curr Opin Lipidol. 2021 Dec 13; doi: 10.1097/MOL.0000000000000805. Epub 2021 Dec 13. PMID: 34907967.
Copy Download .nbib Format: NLM
BYSL Promotes Glioblastoma Cell Migration, Invasion, and Mesenchymal Transition Through the GSK-3β/β-Catenin Signaling Pathway.

Frontiers in oncology

Sha Z, Zhou J, Wu Y, Zhang T, Li C, Meng Q, Musunuru PP, You F, Wu Y, Yu R, Gao S.
PMID: 33178594
Front Oncol. 2020 Oct 15;10:565225. doi: 10.3389/fonc.2020.565225. eCollection 2020.

No abstract available.

Cite
Sha Z, Zhou J, Wu Y, et al. BYSL Promotes Glioblastoma Cell Migration, Invasion, and Mesenchymal Transition Through the GSK-3β/β-Catenin Signaling Pathway. Front Oncol. 2020;10:565225doi: 10.3389/fonc.2020.565225.
Sha, Z., Zhou, J., Wu, Y., Zhang, T., Li, C., Meng, Q., Musunuru, P. P., You, F., Wu, Y., Yu, R., & Gao, S. (2020). BYSL Promotes Glioblastoma Cell Migration, Invasion, and Mesenchymal Transition Through the GSK-3β/β-Catenin Signaling Pathway. Frontiers in oncology, 10565225. https://doi.org/10.3389/fonc.2020.565225
Sha, Zhuang, et al. "BYSL Promotes Glioblastoma Cell Migration, Invasion, and Mesenchymal Transition Through the GSK-3β/β-Catenin Signaling Pathway." Frontiers in oncology vol. 10 (2020): 565225. doi: https://doi.org/10.3389/fonc.2020.565225
Sha Z, Zhou J, Wu Y, Zhang T, Li C, Meng Q, Musunuru PP, You F, Wu Y, Yu R, Gao S. BYSL Promotes Glioblastoma Cell Migration, Invasion, and Mesenchymal Transition Through the GSK-3β/β-Catenin Signaling Pathway. Front Oncol. 2020 Oct 15;10:565225. doi: 10.3389/fonc.2020.565225. eCollection 2020. PMID: 33178594; PMCID: PMC7593785.
Copy Download .nbib Format: NLM
Detoxifying chemotherapy with genetics-guided stem cell modeling: A personalized affair.

Cell stem cell

Brooks DL, Musunuru K.
PMID: 34861143
Cell Stem Cell. 2021 Dec 02;28(12):2039-2040. doi: 10.1016/j.stem.2021.11.006.

Doxorubicin chemotherapy causes cardiotoxicity in some patients and spares others. In this issue of Cell Stem Cell, Magdy et al. (2021) use genome-edited iPSCs to establish a common RARG coding variant as a causal risk factor, pointing to a...

Cite
Brooks DL, Musunuru K. Detoxifying chemotherapy with genetics-guided stem cell modeling: A personalized affair. Cell Stem Cell. 2021;28(12):2039-2040doi: 10.1016/j.stem.2021.11.006.
Brooks, D. L., & Musunuru, K. (2021). Detoxifying chemotherapy with genetics-guided stem cell modeling: A personalized affair. Cell stem cell, 28(12), 2039-2040. https://doi.org/10.1016/j.stem.2021.11.006
Brooks, Dominique L, and Musunuru, Kiran. "Detoxifying chemotherapy with genetics-guided stem cell modeling: A personalized affair." Cell stem cell vol. 28,12 (2021): 2039-2040. doi: https://doi.org/10.1016/j.stem.2021.11.006
Brooks DL, Musunuru K. Detoxifying chemotherapy with genetics-guided stem cell modeling: A personalized affair. Cell Stem Cell. 2021 Dec 02;28(12):2039-2040. doi: 10.1016/j.stem.2021.11.006. PMID: 34861143.
Copy Download .nbib Format: NLM
Defining high-risk elective contralateral neck radiation volumes for oropharynx cancer.

Head & neck

Witek ME, Woody NM, Musunuru HB, Hill PM, Yadav P, Burr AR, Ko HC, Ross RB, Kimple RJ, Harari PM.
PMID: 34761832
Head Neck. 2022 Feb;44(2):317-324. doi: 10.1002/hed.26924. Epub 2021 Nov 11.

BACKGROUND: To define the location of the initial contralateral lymph node (LN) metastasis in patients with oropharynx cancer.METHODS: The location of the LN centroids from patients with oropharynx cancer and a single radiographically positive contralateral LN was defined. A...

Cite
Witek ME, Woody NM, Musunuru HB, et al. Defining high-risk elective contralateral neck radiation volumes for oropharynx cancer. Head Neck. 2021;44(2):317-324doi: 10.1002/hed.26924.
Witek, M. E., Woody, N. M., Musunuru, H. B., Hill, P. M., Yadav, P., Burr, A. R., Ko, H. C., Ross, R. B., Kimple, R. J., & Harari, P. M. (2022). Defining high-risk elective contralateral neck radiation volumes for oropharynx cancer. Head & neck, 44(2), 317-324. https://doi.org/10.1002/hed.26924
Witek, Matthew E, et al. "Defining high-risk elective contralateral neck radiation volumes for oropharynx cancer." Head & neck vol. 44,2 (2022): 317-324. doi: https://doi.org/10.1002/hed.26924
Witek ME, Woody NM, Musunuru HB, Hill PM, Yadav P, Burr AR, Ko HC, Ross RB, Kimple RJ, Harari PM. Defining high-risk elective contralateral neck radiation volumes for oropharynx cancer. Head Neck. 2022 Feb;44(2):317-324. doi: 10.1002/hed.26924. Epub 2021 Nov 11. PMID: 34761832.
Copy Download .nbib Format: NLM
Why Human Embryo Editing Should Be Banned.

The CRISPR journal

Musunuru K.
PMID: 31860349
CRISPR J. 2019 Dec;2(6):356-358. doi: 10.1089/crispr.2019.29078.kmu.

No abstract available.

Cite
Musunuru K. Why Human Embryo Editing Should Be Banned. CRISPR J. 2019;2(6):356-358doi: 10.1089/crispr.2019.29078.kmu.
Musunuru, K. (2019). Why Human Embryo Editing Should Be Banned. The CRISPR journal, 2(6), 356-358. https://doi.org/10.1089/crispr.2019.29078.kmu
Musunuru, Kiran. "Why Human Embryo Editing Should Be Banned." The CRISPR journal vol. 2,6 (2019): 356-358. doi: https://doi.org/10.1089/crispr.2019.29078.kmu
Musunuru K. Why Human Embryo Editing Should Be Banned. CRISPR J. 2019 Dec;2(6):356-358. doi: 10.1089/crispr.2019.29078.kmu. PMID: 31860349.
Copy Download .nbib Format: NLM
Medical misinformation: vet the message!.

Cardiovascular research

Hill JA, Agewall S, Baranchuk A, Booz GW, Borer JS, Camici PG, Chen PS, Dominiczak AF, Erol Ç, Grines CL, Gropler R, Guzik TJ, Heinemann MK, Iskandrian AE, Knight BP, London B, Lüscher TF, Metra M, Musunuru K, Nallamothu BK, Natale A, Saksena S, Picard MH, Rao SV, Remme WJ, Rosenson RS, Sweitzer NK, Timmis A, Vrints C.
PMID: 30689762
Cardiovasc Res. 2019 Jan 28; doi: 10.1093/cvr/cvz007. Epub 2019 Jan 28.

No abstract available.

Cite
Hill JA, Agewall S, Baranchuk A, et al. Medical misinformation: vet the message!. Cardiovasc Res. 2019;doi: 10.1093/cvr/cvz007.
Hill, J. A., Agewall, S., Baranchuk, A., Booz, G. W., Borer, J. S., Camici, P. G., Chen, P. S., Dominiczak, A. F., Erol, �. �., Grines, C. L., Gropler, R., Guzik, T. J., Heinemann, M. K., Iskandrian, A. E., Knight, B. P., London, B., Lüscher, T. F., Metra, M., Musunuru, K., Nallamothu, B. K., Natale, A., Saksena, S., Picard, M. H., Rao, S. V., Remme, W. J., Rosenson, R. S., Sweitzer, N. K., Timmis, A., & Vrints, C. (2019). Medical misinformation: vet the message!. Cardiovascular research, . https://doi.org/10.1093/cvr/cvz007
Hill, Joseph A, et al. "Medical misinformation: vet the message!." Cardiovascular research vol. (2019). doi: https://doi.org/10.1093/cvr/cvz007
Hill JA, Agewall S, Baranchuk A, Booz GW, Borer JS, Camici PG, Chen PS, Dominiczak AF, Erol Ç, Grines CL, Gropler R, Guzik TJ, Heinemann MK, Iskandrian AE, Knight BP, London B, Lüscher TF, Metra M, Musunuru K, Nallamothu BK, Natale A, Saksena S, Picard MH, Rao SV, Remme WJ, Rosenson RS, Sweitzer NK, Timmis A, Vrints C. Medical misinformation: vet the message!. Cardiovasc Res. 2019 Jan 28; doi: 10.1093/cvr/cvz007. Epub 2019 Jan 28. PMID: 30689762.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 57 entries